Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 28, 1998

Primary Completion Date

July 31, 2000

Study Completion Date

June 30, 2015

Conditions
Lymphoma
Interventions
DRUG

fludarabine phosphate

DRUG

octreotide acetate

Trial Locations (20)

55416

CCOP - Metro-Minnesota, Saint Louis Park

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

57709

Rapid City Regional Hospital, Rapid City

58122

CCOP - Merit Care Hospital, Fargo

58201

Altru Health Systems, Grand Forks

58501

Quain & Ramstad Clinic, P.C., Bismarck

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68131

CCOP - Missouri Valley Cancer Consortium, Omaha

70121

CCOP - Ochsner, New Orleans

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

10309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

43623-3456

CCOP - Toledo Community Hospital Oncology Program, Toledo

17822-2001

CCOP - Geisinger Clinical and Medical Center, Danville

57105-1080

CCOP - Sioux Community Cancer Consortium, Sioux Falls

S4S 6X3

Saskatchewan Cancer Agency, Regina

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00002779 - Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter